Literature DB >> 18415020

Fracture risk and bone mineral density in Turner syndrome.

Vladimir K Bakalov1, Carolyn A Bondy.   

Abstract

Bone health is a major lifelong concern in caring for women and girls with Turner syndrome (TS). There is an approximately 25% increase in fracture risk most of which is related to medium or high impact trauma. The long bones, especially of the forearm are predominantly affected. This fact may be due to a selective cortical bone deficiency in TS which is unrelated to hypogonadism. In addition, lack of adequate estrogen replacement can lead to trabecular bone deficiency and increase in vertebral compression fractures after age 45. Evaluation of bone density by dual X-ray absorptiometry (DEXA) is important, however, it should be used judiciously in TS in view of its inherent tendency to underestimate the bone density of people with short stature. Bone size-independent methods, such as QCT or volumetric transformation of DEXA data should be used in individuals shorter than 150 cm. Achieving optimal bone density is of critical importance for fracture prevention in TS, and should be pursued by timely introduction of hormone replacement therapy, adequate dose of estrogens during the young adult life, optimal calcium and vitamin D intake and regular physical exercise. In addition, other measures to prevent fall and trauma should be considered, including optimizing hearing and vision, avoiding contact sports and exercise to improve coordination.

Entities:  

Mesh:

Year:  2008        PMID: 18415020     DOI: 10.1007/s11154-008-9076-2

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  50 in total

1.  Geometry of proximal femur in the prediction of hip fracture in osteoporotic women.

Authors:  S Gnudi; C Ripamonti; G Gualtieri; N Malavolta
Journal:  Br J Radiol       Date:  1999-08       Impact factor: 3.039

2.  Bone mineral density assessed by phalangeal radiographic absorptiometry before and during long-term growth hormone treatment in girls with Turner's syndrome participating in a randomized dose-response study.

Authors:  T C Sas; S M de Muinck Keizer-Schrama; T Stijnen; A van Teunenbroek; W J van Leeuwen; A Asarfi; R R van Rijn; S L Drop
Journal:  Pediatr Res       Date:  2001-09       Impact factor: 3.756

3.  Bone mineral density in adult patients with Turner's syndrome: analyses of the effectiveness of GH and ovarian steroid hormone replacement therapies.

Authors:  Nobuhiko Suganuma; Madoka Furuhashi; Takashi Hirooka; Takayuki Moriwaki; Yukiharu Hasegawa; Osamu Mori; Masamichi Ogawa
Journal:  Endocr J       Date:  2003-06       Impact factor: 2.349

4.  Classic pages in obstetrics and gynecology by Henry H. Turner. A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology, vol. 23, pp. 566-574, 1938.

Authors: 
Journal:  Am J Obstet Gynecol       Date:  1972-05-15       Impact factor: 8.661

5.  The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass.

Authors:  G Saggese; G I Baroncelli; S Bertelloni; S Barsanti
Journal:  J Clin Endocrinol Metab       Date:  1996-08       Impact factor: 5.958

6.  Diagnosis of osteoporosis by planar bone densitometry: can body size be disregarded?

Authors:  S Pors Nielsen; N Kolthoff; O Bärenholdt; B Kristensen; B Abrahamsen; A P Hermann; C Brot
Journal:  Br J Radiol       Date:  1998-09       Impact factor: 3.039

7.  Decreased bone mass despite long-term estrogen replacement therapy in young women with Turner's syndrome and previously normal bone density.

Authors:  R Lanes; P Gunczler; S Esaa; R Martinis; O Villaroel; J R Weisinger
Journal:  Fertil Steril       Date:  1999-11       Impact factor: 7.329

8.  Selective reduction in cortical bone mineral density in turner syndrome independent of ovarian hormone deficiency.

Authors:  Vladimir K Bakalov; Lauren Axelrod; Jeffrey Baron; Lori Hanton; Lawrence M Nelson; James C Reynolds; Suvimol Hill; James Troendle; Carolyn A Bondy
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

Review 9.  Turner syndrome and osteoporosis: mechanisms and prognosis.

Authors:  K Rubin
Journal:  Pediatrics       Date:  1998-08       Impact factor: 7.124

10.  Importance of estrogen on bone health in Turner syndrome: a cross-sectional and longitudinal study using dual-energy X-ray absorptiometry.

Authors:  Wolfgang Högler; Julie Briody; Bin Moore; Sarah Garnett; Pei Wen Lu; Christopher T Cowell
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

View more
  9 in total

1.  Association between ER-α polymorphisms and bone mineral density in patients with Turner syndrome subjected to estroprogestagen treatment--a pilot study.

Authors:  Elżbieta Sowińska-Przepiera; Elżbieta Andrysiak-Mamos; Kornel Chełstowski; Grażyna Adler; Zbigniew Friebe; Anhelli Syrenicz
Journal:  J Bone Miner Metab       Date:  2011-01-27       Impact factor: 2.626

2.  Effects of low-dose estrogen replacement during childhood on pubertal development and gonadotropin concentrations in patients with Turner syndrome: results of a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Charmian A Quigley; Xiaohai Wan; Sipi Garg; Karen Kowal; Gordon B Cutler; Judith L Ross
Journal:  J Clin Endocrinol Metab       Date:  2014-04-24       Impact factor: 5.958

3.  Aberrant neurocognitive processing of fear in young girls with Turner syndrome.

Authors:  David S Hong; Signe Bray; Brian W Haas; Fumiko Hoeft; Allan L Reiss
Journal:  Soc Cogn Affect Neurosci       Date:  2012-11-21       Impact factor: 3.436

Review 4.  The Hypothesis of the Prolonged Cell Cycle in Turner Syndrome.

Authors:  Francisco Álvarez-Nava; Marisol Soto-Quintana
Journal:  J Dev Biol       Date:  2022-05-11

Review 5.  The patient with Turner syndrome: puberty and medical management concerns.

Authors:  Luisa Gonzalez; Selma Feldman Witchel
Journal:  Fertil Steril       Date:  2012-08-09       Impact factor: 7.329

6.  Turner syndrome with primary hyperparathyroidism.

Authors:  Jungmee Park; Yoo-Mi Kim; Jin-Ho Choi; Beom Hee Lee; Jong Ho Yoon; Woon-Young Jeong; Han-Wook Yoo
Journal:  Ann Pediatr Endocrinol Metab       Date:  2013-06-30

7.  Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome.

Authors:  M Chiarito; L Piacente; N Chaoul; P Pontrelli; G D'Amato; A Grandone; G Russo; M E Street; M G Wasniewska; G Brunetti; M F Faienza
Journal:  J Endocrinol Invest       Date:  2022-03-02       Impact factor: 5.467

Review 8.  Bone Fragility in Turner Syndrome: Mechanisms and Prevention Strategies.

Authors:  Maria Felicia Faienza; Annamaria Ventura; Silvia Colucci; Luciano Cavallo; Maria Grano; Giacomina Brunetti
Journal:  Front Endocrinol (Lausanne)       Date:  2016-04-26       Impact factor: 5.555

9.  ESR1 polymorphism (rs2234693) influences femoral bone mass in patients with Turner syndrome.

Authors:  Renata C Scalco; Ericka B Trarbach; Edoarda V A Albuquerque; Thais K Homma; Thais H Inoue-Lima; Mirian Y Nishi; Berenice B Mendonca; Alexander A L Jorge
Journal:  Endocr Connect       Date:  2019-11       Impact factor: 3.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.